US and EU agree on 15 percent tariffs to avert trade war
The announcement came after a private meeting on Sunday between US President Donald Trump and European Commission President Ursula von der Leyen at Trump's Turnberry golf resort in Scotland.
The deal comes just days before Washington was due to impose 30 percent tariffs on EU imports.
'It was a very interesting negotiation. I think it's going to be great for both parties,' Trump told reporters. He added that it was 'a good deal for everybody… a giant deal with lots of countries'.
Von der Leyen welcomed the deal, saying it would 'bring stability; it will bring predictability that's very important for our businesses on both sides of the Atlantic'.
Trump claimed the EU committed to buying about $750bn worth of US energy, increasing investment in the United States by another $600bn and placing a large order for military equipment. Both leaders confirmed that the agreed tariff rate of 15 percent would apply broadly to automobiles and other goods.
'We have the opening up of all of the European countries,' Trump said. Von der Leyen echoed that, noting that the 15 percent rate was 'across the board, all inclusive' and that the European market was effectively now open.
The talks followed months of tense back-and-forth with Trump, who has long accused the EU of unfair trade practices. Just before negotiations began, he called the existing arrangements 'a very one-sided transaction; very unfair to the United States'.
Von der Leyen pointed to the combined economic might of the two powers, describing their trade volume as the world's largest, encompassing 'hundreds of millions of people and trillions of dollars'.
She acknowledged Trump's 'tough' reputation as a negotiator, to which he replied: 'But fair.'
Trade conflict averted
Earlier this month, negotiations appeared close to collapse when Trump threatened to proceed with the 30 percent tariff unless the EU matched the 15 percent terms he recently struck with Japan. Asked if he would accept anything lower, Trump flatly said, 'No'.
Had no agreement been reached, Brussels had prepared a long list of retaliatory tariffs targeting everything from beef and beer to Boeing aircraft and car parts.
German Chancellor Friedrich Merz said that the US-EU deal was a positive move that helped avoid a trade war and a serious blow to the auto sector.
'This agreement has succeeded in averting a trade conflict that would have hit the export-orientated German economy hard,' he said in a statement. 'This applies in particular to the automotive industry, where the current tariffs of 27.5 percent will be almost halved to 15 percent.'
Italian Prime Minister Giorgia Meloni said it was 'positive' that a trade deal had been reached; however, she needed to see the details, Italian news agency ANSA reported.
Trump and United Kingdom Prime Minister Kier Starmer are expected to meet on Monday, with trade also on the agenda. While a separate US–UK trade framework was unveiled in May, Trump insists the broader agreement is already concluded, though the White House admits some elements remain unfinished.
Trump will travel to Aberdeen on Tuesday to help open a third golf course under the family name. He and his sons are expected to cut the ribbon themselves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Jazeera
6 minutes ago
- Al Jazeera
Could Trump's trade strategy forge new alliances against him?
Russia, India, China and Brazil refuse to bend to US tariffs. Brazil, India, China and Russia remain firmly in Donald Trump's sights as targets for his tariffs. Others, like the European Union, have caved and negotiated deals. But could the United States president's confrontational stance forge new alliances, among those who have not, against Trump? Presenter: Adrian Finighan Guests: Einar Tangen – China specialist and senior fellow at the Taihe Institute Gustavo de Carvalho – Senior researcher in the geopolitics of the Global South at the South African Institute of International Affairs David McWilliams – Economist, author and podcast host
Al Jazeera
2 hours ago
- Al Jazeera
Brazil requests World Trade Organization consultation over Trump tariffs
The government of President Luiz Inacio Lula da Silva has petitioned the World Trade Organization for consultations to help alleviate the steep tariffs imposed on Brazil by the United States. Sources within the Brazilian government confirmed the petition on Wednesday to news outlets like AFP and The Associated Press, on condition of anonymity. The aim is to seek relief from the 50 percent tariff that US President Donald Trump slapped on Brazilian exports in response to the country's prosecution of a former far-right president, Jair Bolsonaro. That tariff — the highest Trump has imposed on any country in August — took effect on Wednesday. India, meanwhile, is expected to face 50 percent tariffs later this month, unless a deal is struck beforehand. A request for consultations is usually the first step in the World Trade Organization's trade dispute process. The organisation functions as an international arbiter in economic disputes, though its procedures for negotiating settlements can be lengthy and inconclusive. Brazilian Vice President Geraldo Alckmin has estimated that 35.9 percent of the country's exports to the US will be subject to the stiff taxes. That equals about 4 percent of Brazil's total exports worldwide. Retaliation over Bolsonaro prosecution Trump unveiled the current tariff rate on July 9, in a letter addressed to Lula and published online. Unlike other tariff-related letters at the time, Trump used the correspondence to launch into a barbed attack on the Brazilian government for its decision to prosecute Bolsonaro, an ally, over an alleged coup attempt. 'The way that Brazil has treated former President Bolsonaro, a Highly Respected Leader throughout the World during his Term, including by the United States, is an international disgrace,' Trump wrote. Just as Trump did after his 2020 electoral defeat, Bolsonaro had publicly cast doubt on the results of a 2022 presidential race that saw him lose to Lula. But behind the scenes, police and prosecutors allege that Bolsonaro conspired with his associates to overturn the results of the election. One possible scenario was to declare a 'state of siege' during Bolsonaro's final days as president, as a means of calling up the military and suspending civil rights. Then, a new election would have been called, according to prosecutors. Another idea allegedly floated among Bolsonaro's allies was to poison Lula. But Trump, who likewise faced criminal charges in the past for allegedly attempting to subvert the outcome of a vote, has defended Bolsonaro, calling the prosecution politically biased. 'This trial should not be taking place,' he wrote in the July 9 letter. 'It is a Witch Hunt that should end IMMEDIATELY!' Several weeks later, on July 30, Trump followed up his tariff threat with an executive order that doubled down on his accusations. Not only did Trump accuse Brazil of 'politically persecuting' Bolsonaro, but he added that Brazil was guilty of 'human rights abuses', including the suppression of free speech, through its efforts to stem disinformation on social media. 'Recent policies, practices, and actions of the Government of Brazil threaten the national security, foreign policy, and economy of the United States,' Trump wrote. 'Members of the Government of Brazil have taken actions that interfere with the economy of the United States, infringe the free expression rights of United States persons, violate human rights, and undermine the interest the United States has in protecting its citizens and companies.' Lula speaks out The executive order, however, included an annex that indicated certain products would not be subject to the new US tariffs. They included nuts, orange juice, coal, iron, tin and petroleum products. Lula has claimed that Trump is impeding attempts to negotiate a trade deal between their two countries, a sentiment he repeated in an interview on Wednesday with the news agency Reuters. 'The day my intuition says Trump is ready to talk, I won't hesitate to call him,' Lula told Reuters. 'But today my intuition says he doesn't want to talk. And I'm not going to humiliate myself.' The three-term, left-wing president explained that he saw Trump's tariff threats as part of a long history of US intervention in Brazil and Latin America more broadly. 'We had already pardoned the US intervention in the 1964 coup,' Lula said, referencing the overthrow of a Brazilian president that sparked a two-decade-long military dictatorship 'But this now is not a small intervention. It's the president of the United States thinking he can dictate rules for a sovereign country like Brazil. It's unacceptable.' Lula added that he plans to bolster Brazil's 'national sovereignty' by reforming its mineral extraction policy to boost the local economy. With the US tariffs in play, Lula also explained that he would reach out to members of the BRICS economic trading bloc, named for its founding members: Brazil, Russia, India, China and South Africa. Trump, however, has threatened any BRICS-affiliated country with an additional 10-percent tariff. Lula has been on an English-language media blitz since Trump announced the latest his latest slate of tariffs in July, warning that consumers across the world will be penalised. Late last month, for instance, Lula gave his first interview to The New York Times newspaper in nearly 13 years. When the Times asked what his reaction would be to the tariffs taking effect, Lula expressed ambivalence. 'I'm not going to cry over spilled milk,' he said. 'If the United States doesn't want to buy something of ours, we are going to look for someone who will.'
Al Jazeera
3 hours ago
- Al Jazeera
Wegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk's outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be unavoidable as competition heats up against its blockbuster obesity drug Wegovy amid rising pressure from rival Eli Lilly. Novo Nordisk – which became Europe's most valuable company, worth $650bn, last year on booming sales of Wegovy – is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year, in part due to compounders who have been allowed to make copycat drugs based on the same ingredients as Wegovy due to shortages. Novo Nordisk, which according to its website has 77,000 employees, cut its full-year sales and profit forecasts last week, wiping $95bn off its market value since. The slide is a vast and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the company is eyeing potential cost-cutting measures. Layoffs loom 'We probably won't be able to avoid layoffs,' Jorgensen told Danish broadcaster DR. 'When you have to adjust a company, there are some areas where you have to have fewer people, some [areas] where you have to be smaller.' He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs – known as GLP-1 receptor agonists – was of 'equal size to our business' and compounded versions of Wegovy were sold at a 'much lower price point'. In May, Novo Nordisk said it expected many of the roughly one million US patients using compounded GLP-1 drugs to switch to branded treatments after a US Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million US patients were still using compounded GLP-1s and that the company's lowered outlook has 'not assumed a reduction in compounding' this year. 'The obesity market is volatile,' Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of the firm's new full-year guidance range would be for 'unforeseen events', such as stronger pricing pressure in the US than forecast, he said. The lower end of the range would imply sales around 150 billion Danish krone ($23bn) in the second half of 2025, compared with 157 billion krone ($24.5bn) in the same period last year. Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest US prescription data for Wegovy. While the drug was overtaken earlier this year by rival Eli Lilly's Zepbound in terms of US prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36 percent in the US and more than quadrupled in markets outside the US compared to a year ago, Novo Nordisk said. While Wegovy's US pricing held steady in the quarter, the company expected deeper erosion in the key US market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo Nordisk was expanding its US direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar 'cash sales' directly to patients, outside of insurance channels, in some markets outside the US. Cost cuts Novo Nordisk reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said the company was acting to 'ensure efficiencies in our cost base' as it announced it would terminate eight research and development projects. 'There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence,' Jefferies analysts said in a note. Investors have questioned whether the company can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendations on the stock since last week. Shares in Novo Nordisk plunged 30 percent last week – their worst weekly performance in over two decades. The stock has continued to tumble since the market opened in New York. As of 12pm local time (16:00 GMT), the pharmaceutical giant was down by more than 3.3 percent.
